One case of fulminant type 1 diabetes mellitus induced by allopurinol tablets hypersensitivity syndrome

doi:10.19803/j.1672-8629.20230806

Abstract

Abstract: Objective To explore the correlation between fulminate type 1 diabetes mellitus and allopurinol-induced drug hypersensitivity syndrome, and to provide reference for clinical practice. Methods A patient with HLA-B*5801 allele who developed secondary fulminant type 1 diabetes mellitus after allopurinol-induced hypersensitivity syndrome and was reported. The characteristics of the case and the related mechanism of drug-induced adverse reactions were analyzed according to the relevant literature, and the treatment measures for such patients were sorted out. Results The patient lost islet function completely and needed long-term multiple daily insulin injection to control blood glucose in the future. Previous studies and case reports suggest that this adverse event may be related to the use of allopurinol. Conclusion This case suggests that HLA-B*5801 gene testing should be performed before allopurinol treatment. Clinicians should be aware of the risk of secondary autoimmune diseases associated with drug-induced hypersensitivity syndrome.

Key words: fulminant type 1 diabetes mellitus, allopurinol, adverse reaction, drug-induced hypersensitivity syndrome, HLA-B*5801, drug-indused skin rash, pharmaceutical care

CLC Number:

YAN Yan, LIU Naiyi, QIAO Ling, ZHANG Yi, YANG Chen. One case of fulminant type 1 diabetes mellitus induced by allopurinol tablets hypersensitivity syndrome[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1068-1070.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20230806

https://zgywjj.magtechjournal.com/EN/Y2024/V21/I9/1068

References

[1] Chinese Society of Endocrinology, Chinese Medical Association. Guideline for the diagnosis and management of hyperuricemia and gout in China (2019)[J]. Chinese Journal of Endocrinology and Metabolism(中华内分泌代谢杂志), 2020, 36(1): 1-13.
[2] FITZGERALD JD, DALBETH N, MIKULS T, et al.2020 American college of rheumatology guideline for the management of gout[J]. Arthritis Care Res (Hoboken), 2020, 72(6): 744-760.
[3] YASEEN W, AUGUSTE B, ZIPURSKY J.Allopurinol hypersensitivity syndrome[J]. CMAJ, 2023, 195(13): E483.
[4] CABAÑAS R, RAMÍREZ E, SENDAGORTA E, et al. Spanish guidelines for diagnosis, management, treatment, and prevention of DRESS syndrome[J]. J Investig Allergol Clin Immunol, 2020, 30(4): 229-253.
[5] QIU JL, ZHAN SP, HUANG H, et al.One case report and literaturereview of fulminant type 1 diabetes mellitus caused by drug-induced hypersensitivity syndrome[J]. Chinese Journal of Diabetes(中国糖尿病杂志), 2017, 25(5): 464-467.
[6] IMAGAWA A, TACHIBANA M.Fulminant type 1 diabetes: recent research progress and future prospects[J]. Diabetol Int, 2020, 11(4): 336-341.
[7] ZHANG XZ, YUAN FY, XU D, et al.Fulminant type 1 diabetes mellitus and graves disease caused by drug-induced hypersensitivity syndrome followed by pure red cell aplasia with thymoma: report and literature review[J]. Journal of Rare and Uncommon Diseases(罕少疾病杂志), 2022, 29(7): 8-11.
[8] ONUMA H, TOHYAMA M, IMAGAWA A, et al.High frequency of HLA B62 in fulminant type 1 diabetes with the drug-induced hypersensitivity syndrome[J]. J Clin Endocrinol Metab, 2012, 97(12): E2277-E2281.
[9] SOMMERS LM, SCHOENE RB.Allopurinol hypersensitivity syndrome associated with pancreatic exocrine abnormalities and new-onset diabetes mellitus[J]. Arch Intern Med, 2002, 162(10): 1190-1192.
[10] STIRTON H, SHEAR NH, DODIUK-GAD RP.Drug reaction with eosinophilia and systemic symptoms (DReSS)/drug-induced hypersensitivity syndrome (DiHS)-readdressing the DReSS[J]. Biomedicines, 2022, 10(5): 999.
[11] HAMA N, ABE R, GIBSON A, et al.Drug-induced hypersensitivity syndrome (DIHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): clinical features and pathogenesis[J]. J Allergy Clin Immunol Pract, 2022, 10(5): 1155-1167.
[12] QIU J, YIN W, WANG R, et al.Fulminant type 1 diabetes: focusing on triggering factors[J]. Diabetes Metab Res Rev, 2024,40(2): e3731.
[13] KANO Y, TOHYAMA M, AIHARA M, et al.Sequelae in 145 patients with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms: survey conducted by the Asian research committee on severe cutaneous adverse reactions (ASCAR)[J]. J Dermatol, 2015, 42(3): 276-282.
[14] ZHU B, WU J, CHEN G, et al.Fulminant type 1 diabetes mellitus caused by drug reaction with eosinophilia and systemic symptoms (DRESS): a case report and review of the literature[J]. Front Endocrinol (Lausanne), 2019, 16(10): 474.
[15] KAWASAKI E.Anti-islet autoantibodies in type 1 diabetes[J]. Int J Mol Sci, 2023, 24(12): 10012.
[16] HOSOKAWA Y, HANAFUSA T, IMAGAWA A.Pathogenesis of fulminant type 1 diabetes: genes, viruses and the immune mechanism, and usefulness of patient-derived induced pluripotent stem cells for future research[J]. J Diabetes Investig, 2019, 10(5): 1158-1164.
[17] Chinese Diabetes Society, Chinese Endocrinologist Association, Chinese Society of Endocrinology, Chinese Pediatric Society, Chinese Society of Endocrinology, Chinese Medical Association, et al. Guidelines for the diagnosis and treatment of type 1 diabetes mellitus in China (2021 edition)[J]. Chinese Journal of Diabetes Mellitus(中华糖尿病杂志), 2022, 14(11): 1143-1250.
[18] SAYAMA K, IMAGAWA A, OKITA K, et al.Pancreatic beta and alpha cells are both decreased in patients with fulminant type 1 diabetes: a morphometrical assessment[J]. Diabetologia, 2005, 48(8): 1560-1564.